Drug Database
Back to search

Netherlands· NL-0829041299b9

ELAHERE 5 mg/ml concentraat voor oplossing voor infusie

A mirvetuximab soravtansine product containing mirvetuximab soravtansine, registered in Netherlands by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 13 of our 19 countries.

ATC L01FX26

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedELAHERE 5 mg/ml concentraat voor oplo…ATCL01FX26REGISTER NO.NL-0829041299b9PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mirvetuximab soravtansineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Mirvetuximab soravtansine is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FX26 (mirvetuximab soravtansine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search mirvetuximab soravtansine products by name

Mirvetuximab soravtansine · ATC L01FX26

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MIRVETUXIMAB SORAVTANSINE
Manufacturer
AbbVie Deutschland GmbH & Co. KG
Country
Netherlands (NL)
ATC code
L01FX26
ATC class
Mirvetuximab soravtansine
Defined daily dose
18 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1866

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mirvetuximab soravtansine in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mirvetuximab soravtansine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Elahere
  • Iceland · Elahere
  • Liechtenstein · Elahere
  • Norway · Elahere

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/13614569-7a71-41c7-9ea6-4e9637171aa9
GET /v1/drugs/13614569-7a71-41c7-9ea6-4e9637171aa9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Mirvetuximab soravtansine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132344",
  "excipients": [
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "NATRIUMACETAAT 3-WATER (E 262)",
    "POLYSORBAAT 20 (E 432)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "MIRVETUXIMAB SORAVTANSINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/11/14",
  "procedure_number": "EMEA/H/C/005036",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1866",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about mirvetuximab soravtansine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console